Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunex Enbrel

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA's Arthritis Advisory Committee votes April 11 that etanercept clinical data supports a claim of delaying radiographic progression in patients with early rheumatoid arthritis but votes against the claim for the overall RA population. Enbrel currently is approved for reduction in signs and symptoms of moderately to severely active RA in patients who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs). In the double-dummy, 632-patient Enbrel pivotal trial, patients with highly active disease were randomized to etanercept 10 mg or 25 mg twice-weekly injections, or optimized oral methotrexate (MTX) 20 mg per week. The study was designed to show that Enbrel 25 mg would "preserve at least 70% of the expected benefit of MTX" in preventing progression of disease, as assessed by the Total Sharp Score, a radiographic endpoint measuring erosion and joint space narrowing. The company reported that Enbrel 25 mg "is estimated to have 113% of the predicted MTX treatment effect and…preserves at least 96% of the predicted MTX treatment effect." The committee also endorsed Enbrel's efficacy in treating "signs and symptoms" in patients with early RA who have not received treatment with other DMARDs. The claim was supported by area under the curve measurements of the American College of Rheumatology numeric response (ACR-N) index, which demonstrated a benefit for Enbrel versus methotrexate

You may also be interested in...



Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold

The US FDA appears to have concerns about the device used to administer the vaccine.

US Lab-Testing Certification Process Will Be Streamlined Under Quick-Start Guide, CMS Says

The US Medicare agency has released a quick-start guide for laboratory certification.

Washington State Ecology Mulls ‘Safer’ Definition While Exploring Phthalate Alternatives In Fragrances

Marissa Smith, senior regulatory toxicologist in the Washington Department of Ecology’s Hazardous Waste and Toxics Reduction program, discusses what’s next for the state’s inaugural Safer Products go-round. “How we define ‘safer’ is really going to be the lynchpin of this whole process,” she says.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel